The PBYI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PBYI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The PBYI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View PBYI Detailed Price Forecast - CNN Money||View PBYI Detailed Summary - Google Finance|
|View PBYI Detailed Summary - Yahoo! Finance||View PBYI Stock Research & Analysis - Zacks.com|
|View PBYI Trends & Analysis - Trade-Ideas||View PBYI Major Holders - Barrons|
|View PBYI Call Transcripts - NASDAQ||View PBYI Breaking News & Analysis - Seeking Alpha|
|View PBYI Annual Report - CompanySpotlight.com||View PBYI OTC Short Report - OTCShortReport.com|
|View PBYI Fundamentals - TradeKing||View PBYI SEC Filings - Bar Chart|
|View Historical Prices for PBYI - The WSJ||View Performance/Total Return for PBYI - Morningstar|
|View the Analyst Estimates for PBYI - MarketWatch||View the Earnings History for PBYI - CNBC|
|View the PBYI Earnings - StockMarketWatch||View PBYI Buy or Sell Recommendations - MacroAxis|
|View the PBYI Bullish Patterns - American Bulls||View PBYI Short Pain Metrics - ShortPainBot.com|
|View PBYI Stock Mentions - StockTwits||View PBYI Stock Mentions - PennyStockTweets|
|View PBYI Stock Mentions - Twitter||View PBYI Investment Forum News - Investor Hub|
|View PBYI Stock Mentions - Yahoo! Message Board||View PBYI Stock Mentions - Seeking Alpha|
|View Insider Transactions for PBYI - SECform4.com||View Insider Transactions for PBYI - Insider Cow|
|View PBYI Major Holdings Summary - CNBC||View Insider Disclosure for PBYI - OTC Markets|
|View Insider Transactions for PBYI - Yahoo! Finance||View Institutional Holdings for PBYI - NASDAQ|
|View PBYI Stock Insight & Charts - FinViz.com||View PBYI Investment Charts - StockCharts.com|
|View PBYI Stock Overview & Charts - BarChart||View PBYI User Generated Charts - Trading View|
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Posted on Thursday October 18, 2018
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, November 1, 2018 following release of its third quarter 2018 financial results. Please dial in at least ten minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at http://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after completion of the call and will be archived on Puma’s website for 90 days.
Puma Biotech (PBYI) Rides High on Robust Nerlynx Performance
Posted on Thursday October 18, 2018
Puma Biotech (PBYI) focuses on improving sales of its flagship and the only approved product Nerlynx. The drug's label expansion programs also appear promising.
Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis — Discovering Underlying Factors of Influence
Posted on Wednesday October 17, 2018
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Celcuity Announces Clinical Trial Collaboration with Puma Biotechnology and West Cancer Center
Posted on Tuesday October 16, 2018
Celcuity Inc. (CELC), a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, today announced a clinical trial agreement with Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, and West Cancer Center, to conduct a Phase II clinical trial. This open-label Phase II trial will evaluate the efficacy and safety of Puma’s drug, NERLYNX ®(neratinib), and chemotherapy in up to 27 early stage triple-negative breast cancer patients selected with Celcuity’s CELx HER2 Signaling Function (“CELx HSF”) Test. Under this agreement, West Cancer Center will serve as the sponsor and principal investigator of the trial and is responsible for enrolling patients and managing clinical data.